Strategic move aims to boost share value amid recovery
Outset Medical announced a 1-for-15 reverse stock split, effective March 20, 2025. Shares will continue trading under the OM ticker on a split-adjusted basis.
The move reduces total outstanding shares from 265 million to approximately 17 million, with no impact on shareholder ownership percentages (excluding fractional shares). The decision was approved at a March 5 special meeting.
The company, known for its Tablo home hemodialysis system, is rebounding after resolving an FDA warning. It projects 2025 revenue between $115–$125 million, a high-30% non-GAAP gross margin, and reduced cash burn of under $50 million, backed by a $169 million financing round.
Follow MEDWIRE.AI for financial moves and medtech recovery trends.
